These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28094040)

  • 21. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
    Semrad TJ; Kim EJ; Gong IY; Li T; Christensen S; Arora M; Riess JW; Gandara DR; Kelly K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):335-341. PubMed ID: 33993383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas.
    Song A; Andrews DW; Werner-Wasik M; Kim L; Glass J; Bar-Ad V; Evans JJ; Farrell CJ; Judy KD; Daskalakis C; Zhan T; Shi W
    Radiother Oncol; 2019 Mar; 132():135-141. PubMed ID: 30825962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
    Shah HA; Fischer JH; Venepalli NK; Danciu OC; Christian S; Russell MJ; Liu LC; Zacny JP; Dudek AZ
    Am J Clin Oncol; 2019 May; 42(5):413-420. PubMed ID: 30973373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
    Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
    EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
    Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
    Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
    Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
    Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
    Melichar B; Adenis A; Lockhart AC; Bennouna J; Dees EC; Kayaleh O; Obermannova R; DeMichele A; Zatloukal P; Zhang B; Ullmann CD; Schusterbauer C
    Lancet Oncol; 2015 Apr; 16(4):395-405. PubMed ID: 25728526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
    Smith HO; Blessing JA; Vaccarello L
    Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Gallup DG; Blessing JA; Andersen W; Morgan MA;
    Gynecol Oncol; 2003 Apr; 89(1):48-51. PubMed ID: 12694653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Kelly KR; Shea TC; Goy A; Berdeja JG; Reeder CB; McDonagh KT; Zhou X; Danaee H; Liu H; Ecsedy JA; Niu H; Benaim E; Iyer SP
    Invest New Drugs; 2014 Jun; 32(3):489-99. PubMed ID: 24352795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
    Tayyar Y; Jubair L; Fallaha S; McMillan NAJ
    Crit Rev Oncol Hematol; 2017 Nov; 119():59-65. PubMed ID: 29065986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
    Upadhyaya SA; Campagne O; Billups CA; Orr BA; Onar-Thomas A; Tatevossian RG; Mostafavi R; Myers JR; Vinitsky A; Moreira DC; Lindsay HB; Kilburn L; Baxter P; Smith A; Crawford JR; Partap S; Bendel AE; Aguilera DG; Nichols KE; Rampersaud E; Ellison DW; Klimo P; Patay Z; Robinson GW; Broniscer A; Stewart CF; Wetmore C; Gajjar A
    Neuro Oncol; 2023 Feb; 25(2):386-397. PubMed ID: 35652336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
    Mackay HJ; Buckanovich RJ; Hirte H; Correa R; Hoskins P; Biagi J; Martin LP; Fleming GF; Morgan R; Wang L; Polintan R; Oza AM
    Gynecol Oncol; 2012 Apr; 125(1):136-40. PubMed ID: 22138373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
    Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study.
    Slayton RE; Blessing JA; Look K; Anderson B
    Invest New Drugs; 1991 May; 9(2):207-8. PubMed ID: 1874603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.